AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

Inclusion Criteria

• •Leukocytes \>= 3,000/mcL
• •Histologically or cytologically confirmed soft tissue sarcoma including, but not limited to any of:
• •* Malignant fibrous histiocytoma
• •* Fibrosarcoma - non infantile
• •* Leiomyosarcoma - not uterine
• •* Liposarcoma
• •* Non-rhabdomyosarcoma soft tissue sarcoma
• •* Rhabdomyosarcoma, not otherwise specified
• •* Carcinosarcoma of the uterus
• •* Dermatofibrosarcoma
• •* Endometrial stromal sarcoma
• •* Leiomyosarcoma - uterus
• •Recurrent or locally advanced or metastatic disease
• •* No more than two prior lines of chemotherapy for metastatic disease (not including adjuvant chemotherapy)
• •Measurable disease, defined as \>= 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques or \>= 10 mm by spiral CT scan
• •* Target measurable lesion must not have been in previous radiation portal, unless progression of this lesion after radiotherapy has been documented
• •ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%
• •Life expectancy \> 12 weeks
• •Recovered from all prior therapy
• •Platelet count \>= 100,000/mcL
• •Hemoglobin \> 9 g/dL
• •Total bilirubin =\< 1.25 times upper limit of normal (ULN)
• •AST and ALT =\< 3 times ULN
• •Creatinine =\< 1.5 times ULN OR creatinine clearance \>= 50 mL/min
• •Urine protein:creatinine ratio =\< 1.0 OR 24-hour urine protein \< 1,000 mg
• •ANC \>1,500/mcL
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 8 weeks after completion of study therapy
• •No history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530
• •No QTc prolongation (defined as a QTc interval \>= to 460 msecs) or other significant ECG abnormalities
• •No poorly controlled hypertension (i.e., systolic blood pressure (BP) \>= 140 mm Hg, or diastolic BP \>= 90 mm Hg)
• •No condition that impairs a patient's ability to swallow AZD0530 tablets, including any of the following:
• •* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
• •* Prior surgical procedures affecting absorption
• •* Active peptic ulcer disease